期刊文献+

苯扎贝特的合成研究 被引量:4

Study on Synthesis of Bezafibrate
下载PDF
导出
摘要 苯扎贝特是第二代苯氧乙酸类调脂药,主要用于IIb、III、IV型高血脂症的治疗。讲述苯扎贝特是以对羟基苯甲醛、盐酸盐、氯化物、氯仿为主要原料,通过酰化,缩合,等工序合成苯扎贝特,分析了合成过程中滴加速度、回流时间、反应pH值、反应温度等因素影响,并对苯扎贝特的熔点、水分、含量进行了检测。 Bezafibrate is the second generation phenyloxycarboxylic acid medicine , Bezafibrate is prepared from hydroxy benzaldehyde, hydrochloride, chloride and chloroform, Its four manufacturing processes are: acylation, condensation, pulping and refinemont. The requirements on reaction conditions are also very high. In this paper, the processes and the importance of reaction conditions were introduced. Through examination of the melting point, the moisture content, the content to the bezafibrate, the preparation craft was confirmed to be feasible.
作者 陈亚萍
出处 《辽宁化工》 CAS 2007年第11期733-735,738,共4页 Liaoning Chemical Industry
关键词 苯扎贝特 降脂药物 合成 Bezafibrate Generation pHenyloxycarboxylic acid medicine Synthesis
  • 相关文献

参考文献6

二级参考文献27

  • 1吴洁.反相高效液相色谱法测定苯扎贝特的含量[J].化学试剂,2004,26(5):285-286. 被引量:5
  • 2王亚楼,谢冬梅.酪胺合成方法的改进[J].中国药物化学杂志,1994,4(2):128-129. 被引量:4
  • 3[2]Ahmed Trfesh;B.Frank Wood;Joseph A.McDonough;Graham N.Mott.Process for the preparation of arylethylamines and substituted arylethylamines[ P].US :5220067,1993-6-15 被引量:1
  • 4Executive Summary of the Third Report of The National Cholesterol Education Program(NCEP) Expert Panel on Detection, Evaluation, And Treatment of High Blood Cholesterol In Adults. ( Adult Treatment Panel Ⅲ). JAMA, 2001,285:2486-2497. 被引量:1
  • 5Grundy SM. Obesity , metabolic syndrome, and atherosclerosis.Circulation, 2002, 105:2696-2698. 被引量:1
  • 6Assemann G, Schulte H, Cullen P. New and classical risk factorsthe Münster heart study(PROCAM). Eur J Med Res ,1997,2:237-242. 被引量:1
  • 7Hokanson JE, Austin MA. Plasma triglyceride level is a risk factor for cardiovascular disease independent of high-density lipoprotein cholesterol level: a meta-analysis of population-based prospective studies. J Cardiovasc Risk,1996,3:213-219. 被引量:1
  • 8Grundy SM. Low-density lipoprotein,non-high density lipoprotein,and apoprotein B as targets of lipid-lowering therapy. Circulation,2002,106, 2526-2529. 被引量:1
  • 9Sacks FM , Tonkin AM, Craven T, et al. Coronary hart disease in patients with low LDL-chesterol: benefit of pravastatin in diabeties and enhanced role for HDL-cholesterol and triglycerides as risk factors. Circulation,2002, 105 : 1424-1428. 被引量:1
  • 10Rubins HB, Robins SJ, Collins D, et al. Gemfibrozil for the secondary prevention of coronary heart disease in men with low levels of high-density lipoprotein cholesterol. Veterans Affairs High-Density Lipoprotein Cholesterol Intervention Trial Study Group. N Engl J Med ,1999,341:410-418. 被引量:1

共引文献32

同被引文献19

  • 1吴洁.苯扎贝特合成过程中的杂质分离及工艺改进[J].中国现代应用药学,2006,23(4):301-302. 被引量:2
  • 2吕国平,郑智慧,赵宝华,向四海,董悦生,王富强,张华.PPARδ激动剂高通量筛选模型的建立[J].生物工程学报,2007,23(2):343-346. 被引量:7
  • 3PETER B. Process for the preparation of α-[4-(4-chlorobenzoylaminoethyl) -phenoxy ]-isobutyric acid : US ,4370495 [ P]. 1983 - 01 - 25. 被引量:1
  • 4BOEHRINGER MANNHEIM GMBH. Phenoxyalkylcarbonsaurederivate and verfahrenzur herstellung derselben : DE, 2149070 [ P ]. 1973 - 04 - 05. 被引量:1
  • 5Peter B. Process for the preparation of α-[4-(4- chlorobenzoylaminoethyl)phenoxy]isobutyric acid: US, 4370495 [P]. 1983-01-25. (CA 1980, 93: 94997). 被引量:1
  • 6Boehringer Mannheim GmbH. Phenoxyalkylcarbonsaurederi vate and Verfahrenzur Herstellung Derselben: DE, 2149070 [P]. 1973-04-05. 被引量:1
  • 7Peter B. Process for the preparation d a- [4- (4- chlorobenzoylaminoethyl) phenoxy] isobutyrie acid: US,4370495 [ P]. 1983 - 01 - 25 ( CA1980, 93:94997 ):. 被引量:1
  • 8DESIDERI G, GROCE G, TUCCI M, et al. Effects of Benzafibrate and Simvastatin on endothelial activation and lipid peroxidation in hypercholesterolemia:-evidence of different vascular protection by different lipid-lowering treatments [J]. J. Vasc. Surg. , 2004,39 ( 4 ) : 920-931. 被引量:1
  • 9BILSEN M, NIEUWENHOVEN F A. PPARs as therapeu- tic targets in cardiovascular disease [J]. Expert Opin. T-her. Tar. ,2010,14(10):1 029-1 045. 被引量:1
  • 10BANDGAR B P, SARANGDHAR R J, FRUTHOUS K, et al. Synthesis and biological evaluation of ester prodrugs of Benzafibrate as orally active hypo-lipidemic agents [J]. Eur. J. Med. Chem. ,2012,57,217-224. 被引量:1

引证文献4

二级引证文献12

相关作者

内容加载中请稍等...

相关机构

内容加载中请稍等...

相关主题

内容加载中请稍等...

浏览历史

内容加载中请稍等...
;
使用帮助 返回顶部